ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.23%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$597M
AUM Growth
+$597M
(+20%)
Cap. Flow
+$37.8M
Cap. Flow
% of AUM
6.34%
Top 10 Holdings %
Top 10 Hldgs %
54.95%
Holding
336
New
84
Increased
76
Reduced
73
Closed
71
Top Buys
| 1 |
Immunovant
IMVT
|
$18.7M |
| 2 |
Ascendis Pharma
ASND
|
$16.4M |
| 3 |
Zura Bio
ZURA
|
$15.3M |
| 4 |
Zai Lab
ZLAB
|
$12.3M |
| 5 |
AAM
AA Mission Acquisition Corp.
AAM
|
$10.1M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$28M |
| 2 |
Roivant Sciences
ROIV
|
$13M |
| 3 |
Edgewise Therapeutics
EWTX
|
$11.2M |
| 4 |
Merck
MRK
|
$8.47M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$6.96M |
Sector Composition
| 1 | Healthcare | 88.63% |
| 2 | Financials | 3.75% |
| 3 | Communication Services | 0.59% |
| 4 | Utilities | 0.21% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cytokinetics
CYTK
$4.23B
| $48.1M | 7.82% | 911,182 +57,320 | +7% | +$3.03M |
|
|
2
Protagonist Therapeutics
PTGX
$3.67B
| $44.2M | 7.18% | 981,295 -622,637 | -39% | -$28M |
|
3
BridgeBio Pharma
BBIO
$9.89B
| $36.9M | 6% | 1,448,470 +183,900 | +15% | +$4.68M |
|
4
Alpha Architect 1-3 Month Box ETF
BOXX
$7.91B
| $35.2M | 5.73% | 323,382 -28,100 | -8% | -$3.06M |
|
|
5
Roivant Sciences
ROIV
$8.15B
| $34.9M | 5.68% | 3,025,450 -1,124,559 | -27% | -$13M |
|
|
6
Immunovant
IMVT
$2.56B
| $32.3M | 5.25% | 1,131,707 +655,164 | +137% | +$18.7M |
|
7
Royalty Pharma
RPRX
$15.6B
| $31M | 5.05% | 1,096,666 -84,666 | -7% | -$2.4M |
|
8
Keros Therapeutics
KROS
$618M
| $25.8M | 4.2% | 445,068 -103,848 | -19% | -$6.03M |
|
|
9
Ascendis Pharma
ASND
$11.8B
| $24.1M | 3.92% | 161,402 +110,139 | +215% | +$16.4M |
|
|
10
Zura Bio
ZURA
$133M
| $15.3M | 2.49% | +3,770,649 | New | +$15.3M |
|
|
11
Zai Lab
ZLAB
$3.68B
| $12.9M | 2.09% | 532,454 +510,454 | +2,320% | +$12.3M |
|
12
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $10.9M | 1.77% | 436,668 +322,359 | +282% | +$8.06M |
|
|
AAM
13
AA Mission Acquisition Corp.
AAM
$462M
| $10.1M | 1.65% | +1,010,199 | New | +$10.1M |
|
14
Mineralys Therapeutics
MLYS
$1.03B
| $8.83M | 1.44% | 729,401 +704,035 | +2,776% | +$8.53M |
|
15
Arbutus Biopharma
ABUS
$711M
| $8.04M | 1.31% | 2,089,321 -1,199,939 | -36% | -$4.62M |
|
16
Solid Biosciences
SLDB
$427M
| $7.98M | 1.3% | 1,145,592 -274,830 | -19% | -$1.92M |
|
17
Merus
MRUS
$4.98B
| $7.66M | 1.25% | 153,286 +126,436 | +471% | +$6.32M |
|
18
Rezolute
RZLT
$619M
| $7.62M | 1.24% | 1,571,705 -492,257 | -24% | -$2.39M |
|
|
PCSC
19
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.52M | 1.22% | 750,000 | – | – |
|
20
Xencor
XNCR
$580M
| $6.88M | 1.12% | +342,262 | New | +$6.88M |
|
21
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.74M | 1.1% | +350,206 | New | +$6.74M |
|
22
AnaptysBio
ANAB
$569M
| $6.46M | 1.05% | 192,720 +36,921 | +24% | +$1.24M |
|
|
ABVX
23
Abivax
ABVX
$6.12B
| $6.01M | 0.98% | 521,612 +494,612 | +1,832% | +$5.7M |
|
24
Regenxbio
RGNX
$451M
| $5.97M | 0.97% | 569,008 +566,308 | +20,974% | +$5.94M |
|
25
Biogen
BIIB
$19.4B
| $5.74M | 0.93% | +29,625 | New | +$5.74M |
|